A Multi Dose, Open-Label, Parallel-Group Study to Evaluate the PK and Safety/Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder
Latest Information Update: 24 Jan 2025
Price :
$35 *
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics; Registrational
- Acronyms STARLYNG-1
- Sponsors Lyndra
- 21 Jan 2025 According to a Lyndra Therapeutics media release, the US biopharma company said the round, led by Sarissa Capital with participation from Sun Pharmaceutical Industries and Polaris Partners, will support the completion of a pivotal Phase III trial investigating its risperidone candidate LYN-005 in schizophrenia and schizoaffective disorder patients.
- 04 Jan 2024 According to a Lyndra Therapeutics media release, Status changed from recruiting to discontinued.
- 04 Jan 2024 According to a Lyndra Therapeutics media release, Primary endpoint (Average Concentration Over the Dosing Interval (Cavg) at Week 5) has been met.